Physician
Apostol, Melecio
Apostol, Melecio was paid $1.11M by Medicaid between Mar 2018 and Feb 2024, across 52 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 23% of everything it billed.
33Billing provider infoAPOSTOL, MELECIO
ROCKPORT, TX 78382
ROCKPORT, TX 78382
33aNPI1063420404assigned 08/03/2006
33bProvider typePediatrics Physician
28Total paid$1.11M
24GClaims59,718
24DCodes billed52
24AFirst – last monthMar 2018 – Feb 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#355 of 1,136
Median peer was paid$329K
This provider vs. median3.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37 | $1K | |
| 2019 | 16 | $590.24 | |
| 2020 | 2,654 | $47K | |
| 2021 | 19,410 | $354K | |
| 2022 | 21,729 | $395K | |
| 2023 | 15,362 | $295K | |
| 2024incomplete | 510 | $13K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 17,006 | 14,645 | $258K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 15% | 1,997 | 1,946 | $167K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 13% | 1,758 | 1,659 | $140K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 12% | 1,520 | 1,478 | $135K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 11% | 1,274 | 1,242 | $123K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 8.7% | 9,219 | 3,904 | $96K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.5% | 1,615 | 1,512 | $61K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 3.1% | 4,073 | 3,398 | $34K |
| 99381 | 2.0% | 292 | 242 | $22K | |
| 90461 | 1.3% | 3,153 | 2,543 | $14K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,100 | 957 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,676 | 1,593 | $9K |
40 more codes
| 99203 | Doctor's office visit, new patient (routine) | <1% | 223 | $7K |
| 86328 | <1% | 365 | $5K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 188 | $5K |
| 99050 | <1% | 93 | $4K | |
| 99383 | <1% | 41 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 677 | $4K |
| CP002 | <1% | 315 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 327 | $2K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 32 | $1K |
| 83655 | <1% | 151 | $929.63 | |
| 92587 | <1% | 161 | $788.97 | |
| 96160 | <1% | 832 | $738.96 | |
| 92551 | <1% | 1,013 | $313.28 | |
| 87807 | <1% | 93 | $310.20 | |
| 83026 | <1% | 122 | $93.74 | |
| 90686 | <1% | 446 | $61.50 | |
| 99429 | <1% | 12 | $35.00 | |
| 81002 | <1% | 28 | $31.17 | |
| 90723 | 0% | 389 | $0.00 | |
| 90698 | 0% | 116 | $0.00 | |
| 90697 | 0% | 255 | $0.00 | |
| 96127 | 0% | 1,730 | $0.00 | |
| 90680 | 0% | 727 | $0.00 | |
| 90620 | 0% | 30 | $0.00 | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | 0% | 169 | $0.00 |
| 90651 | 0% | 193 | $0.00 | |
| 90696 | 0% | 212 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 15 | $0.00 |
| 90710 | 0% | 687 | $0.00 | |
| 90633 | 0% | 783 | $0.00 | |
| 90715 | 0% | 139 | $0.00 | |
| 90648 | 0% | 771 | $0.00 | |
| 90700 | 0% | 297 | $0.00 | |
| 90670 | 0% | 1,406 | $0.00 | |
| 99173 | 0% | 1,171 | $0.00 | |
| 90734 | 0% | 379 | $0.00 | |
| 90681 | 0% | 191 | $0.00 | |
| 90685 | 0% | 74 | $0.00 | |
| 84030 | 0% | 169 | $0.00 | |
| 90707 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.